Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives

CLEVELAND, OHIO – (September 25, 2020) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a drug development company dedicated to unlocking the unique therapeutic powers of cannabinoids, today announced that it has retained DelMorgan & Co., an internationally recognized investment banking firm, to advise Vitality on its strategic alternatives, including potential financings, asset...

Vitality Biopharma Board Update

CLEVELAND, OHIO – (April 27, 2020)— Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, today announced that Dr. Anthony Maida has decided to resign from its Board of Directors. Dr. Maida had served on Vitality’s Board of Directors since 2012 and had...

Vitality Biopharma Welcomes New Executive Management Team

– Appointment of Current Director Michael Cavanaugh as Interim Chief Executive Officer – – Promotion of Current Controller and Counsel Richard McKilligan to Chief Financial Officer – LOS ANGELES, CA (MARKETWIRED – May 14, 2019) – Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...

Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors

LOS ANGELES, CA – (April 25, 2019) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Dr. Avtar Dhillon has decided to resign...

Vitality Biopharma Appoints Former Ohio Governor Richard F. Celeste to Board

LOS ANGELES, Jan. 24, 2019 — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that it has added an additional position on...

Vitality Biopharma to Present at the 11th Annual LD Micro Main Event

LOS ANGELES, CA – (GLOBE NEWSWIRE – December 3, 2018) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the...

Vitality Biopharma Announces Corporate Updates and Completion of an SEC Examination

Company appoints two new directors including the Hon. Edward Feighan as new Chairman of the Board LOS ANGELES, CA – (MARKETWIRED – November 20, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Vitality Biopharma Receives $8.5 Million Common Stock Financing

Financing to support company at least into 2020 and for the initiation of multiple Phase 2 clinical trials LOS ANGELES, CA – (October 23, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Vitality Biopharma Announces Neural Repair Treatment Patent Filings

Focused on remyelination, a form of neural repair that may benefit multiple sclerosis as well as addiction, stroke, and schizophrenia LOS ANGELES, CA – (October 3, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Vitality Biopharma Scientific Co-Founder to Present Recent Data at CannMed Medical Conference in Los Angeles

Dr. Brandon Zipp to discuss outlook for Vitality’s VBX-100 THC prodrug in scientific presentation held at UCLA LOS ANGELES, CA – (September 13, 2018) – Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment...